<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563509</url>
  </required_header>
  <id_info>
    <org_study_id>2013ZX10001004</org_study_id>
    <nct_id>NCT02563509</nct_id>
  </id_info>
  <brief_title>Reconstitution of HIV-specific Immunity Against HIV</brief_title>
  <official_title>Reconstitution of HIV-specific Immunity Against HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou 8th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou 8th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research Goal: To reconstitute the anti-HIV specific immunity system of the AIDS patients, so
      the viruses could not massively replicate when HAART was discontinued, then make HIV
      functional cure possible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research aims at establishing a new treatment strategies of HIV. It will significantly
      improve the clinical therapy effects and effectively reduce the morbidity and mortality by
      reconstituting the immune systems of HIV infected patients and combining multiple therapy
      strategies. Therefore, the research could develop an cloning amplification system of
      immunocytes in vitro, and improve the antiviral immune system severely damaged before by
      transfusing the clone cells modified by specific HIV antigen. So HIV infected patients could
      discontinue the traditional anti-viral drug, but not develop opportunistic infections,which
      could obviously increase the life qualities of these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number and function of HIV-specific CD8 cells in patients with HIV</measure>
    <time_frame>6 Months</time_frame>
    <description>The change of differentiation, proliferation, apoptosis, phenotype, etal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All adverse events</measure>
    <time_frame>6 Months</time_frame>
    <description>Chills, Fever, Headache, Nausea, Vomiting, Cough, Skin rashes, Anaphylactic shock, Etal.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>HIV-specific CD8 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfusing HIV-specific CD8 cells 50-100mlonce a week for four times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regualar therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only receiving Highly active anti-retroviral therapy(HAART).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-specific CD8 cells</intervention_name>
    <description>Based on HAART, receive HIV-specific CD8 cells transfuion.</description>
    <arm_group_label>HIV-specific CD8 cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV infection confirmed

          2. Receiving HAART more than 6 months

          3. HIV viral-load &lt; 50 copies/ml

          4. Without serious damage of liver and kidney

          5. The subject volunteered to the research and sign the informed consent

        Exclusion Criteria:

          1. With serious opportunistic infections

          2. With serious chronic disease such like diabetes, the mental illness,et al

          3. History of suffering from pancreatitis during HAART.

          4. Pregnant and breast-fed.

          5. With poor adherence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Zhang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou 8th People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Fidler S, Olson A, Fox J, Phillips A, Morrison C, Thornhill J, Bucher H, Muga R, Porter K. The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19820. doi: 10.7448/IAS.17.4.19820. eCollection 2014.</citation>
    <PMID>25397564</PMID>
  </reference>
  <reference>
    <citation>Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol. 2014 Nov;12(11):750-64. doi: 10.1038/nrmicro3352. Review.</citation>
    <PMID>25402363</PMID>
  </reference>
  <reference>
    <citation>Chew N, Tan E, Li L, Lim R. HIV-1 tat and rev upregulates osteoclast bone resorption. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19724. doi: 10.7448/IAS.17.4.19724. eCollection 2014.</citation>
    <PMID>25397470</PMID>
  </reference>
  <reference>
    <citation>Abdel-Mohsen M, Deng X, Danesh A, Liegler T, Jacobs ES, Rauch A, Ledergerber B, Norris PJ, Günthard HF, Wong JK, Pillai SK. Role of microRNA modulation in the interferon-α/ribavirin suppression of HIV-1 in vivo. PLoS One. 2014 Oct 2;9(10):e109220. doi: 10.1371/journal.pone.0109220. eCollection 2014.</citation>
    <PMID>25275557</PMID>
  </reference>
  <reference>
    <citation>Vandergeeten C, Fromentin R, DaFonseca S, Lawani MB, Sereti I, Lederman MM, Ramgopal M, Routy JP, Sékaly RP, Chomont N. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood. 2013 May 23;121(21):4321-9. doi: 10.1182/blood-2012-11-465625. Epub 2013 Apr 15.</citation>
    <PMID>23589672</PMID>
  </reference>
  <reference>
    <citation>Cahn P, Ruxrungtham K, Gazzard B, Diaz RS, Gori A, Kotler DP, Vriesema A, Georgiou NA, Garssen J, Clerici M, Lange JM; (BTE) Blinded Nutritional Study for Immunity and Tolerance Evaluation Study Team. The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). Clin Infect Dis. 2013 Jul;57(1):139-46. doi: 10.1093/cid/cit171. Epub 2013 Mar 19.</citation>
    <PMID>23511299</PMID>
  </reference>
  <results_reference>
    <citation>Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, Levin D, Wijeyesinghe S, Makamdop KN, del Prete GQ, Hill BJ, Timmer JK, Reiss E, Yarden G, Darko S, Contijoch E, Todd JP, Silvestri G, Nason M, Norgren RB Jr, Keele BF, Rao S, Langer JA, Lifson JD, Schreiber G, Douek DC. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature. 2014 Jul 31;511(7511):601-5. doi: 10.1038/nature13554. Epub 2014 Jul 9.</citation>
    <PMID>25043006</PMID>
  </results_reference>
  <results_reference>
    <citation>Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, De Wit S, Clumeck N, Lambotte O, Rouzioux C, Rohr O, Van Lint C. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS. 2012 Jul 31;26(12):1473-82. doi: 10.1097/QAD.0b013e32835535f5. Erratum in: AIDS. 2013 Jun 19;27(10):1683.</citation>
    <PMID>22555163</PMID>
  </results_reference>
  <results_reference>
    <citation>Crawford TQ, Hecht FM, Pilcher CD, Ndhlovu LC, Barbour JD. Activation associated ERK1/2 signaling impairments in CD8+ T cells co-localize with blunted polyclonal and HIV-1 specific effector functions in early untreated HIV-1 infection. PLoS One. 2013 Oct 15;8(10):e77412. doi: 10.1371/journal.pone.0077412. eCollection 2013.</citation>
    <PMID>24143233</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>April 22, 2018</last_update_submitted>
  <last_update_submitted_qc>April 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou 8th People's Hospital</investigator_affiliation>
    <investigator_full_name>Linghua LI</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>cellular immunity therapy</keyword>
  <keyword>functional cure</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

